

ORIGINAL PAPER

Adjunctive homeopathic treatment in patients with severe sepsis: a randomized, double-blind, placebo-controlled trial in an intensive care unit

M Frass^{1,*}, M Linkesch², S Banyai^{2,3}, G Resch¹, C Dielacher², T Löbl², C Endler¹, M Haidvogel¹, I Muchitsch¹ and E Schuster⁴

¹Ludwig Boltzmann Institute for Homeopathy, Graz, Austria

²II Department of Internal Medicine, University of Vienna, Vienna, Austria

³Cantonal Hospital of Lucerne

⁴Department of Medical Computer Sciences, University of Vienna, Vienna, Austria

Background: Mortality in patients with severe sepsis remains high despite the development of several therapeutic strategies. The aim of this randomized, double-blind, placebo-controlled trial was to evaluate whether homeopathy is able to influence long-term outcome in critically ill patients suffering from severe sepsis.

Methods: Sixty-seven patients with severe sepsis received homeopathic treatment ($n = 33$) or placebo ($n = 34$). Five globules in a potency of 200c were given at 12 h interval during the stay at the intensive care unit. Survival after a 30 and 180 days was recorded.

Results: Baseline characteristics including age, sex, BMI, prior conditions, APACHE II score, signs of sepsis, number of organ failures, need for mechanical ventilation, need for vasopressors or veno-venous hemofiltration, and laboratory parameters were not significantly different between groups. On day 30, there was non-statistically significant trend of survival in favour of homeopathy (verum 81.8%, placebo 67.7%, $P = 0.19$). On day 180, survival was statistically significantly higher with verum homeopathy (75.8% vs 50.0%, $P = 0.043$). No adverse effects were observed.

Conclusions: Our data suggest that homeopathic treatment may be an useful additional therapeutic measure with a long-term benefit for severely septic patients admitted to the intensive care unit. A constraint to wider application of this method is the limited number of trained homeopaths. *Homeopathy* (2005) 1, 234–241.

Keywords: APACHE II; homeopathy; critically ill patients; intensive care unit; sepsis; survival; double-blind; randomized prospective; placebo-controlled study

Introduction

The incidence of severe sepsis is 70,000 to 300,000 patients in the United States each year.¹ Septic shock is associated with mortality rates ranging from 40% to 90%.² Several new therapeutic approaches have failed

during the last decades. Recent guidelines¹ recommend use of goal directed therapy, low-tidal ventilation, administration of recombinant Protein C (aPC), close monitoring of blood glucose with a target value of 80–100 mg/dl, and administration of hydrocortisone. Despite these therapeutic strategies, mortality has remained almost unchanged during the last few years.

Homeopathic medicine has been used for about two centuries. Several studies describe its superiority above placebo.^{3–5} Experimental studies demonstrate the effect of high dilutions^{6,7} even beyond Avogadro's

*Correspondence: M Frass, Ludwig Boltzmann Institute for Homeopathy, Duerergasse 4, A 8010 Graz, Austria.

E-mail: michael.frass@kabsi.at

Received 3 August 2004; revised 11 January 2005; accepted 26 January 2005

number.⁷ There are several case reports on the beneficial effect of homeopathy in critically ill patients.⁸ We initiated this study to investigate the effect of homeopathy on the outcome of critically ill patients. The aim of this prospective, randomized, double-blind, placebo-controlled trial was to evaluate at two time points (30 and 180 days) whether homeopathy can influence outcome in patients suffering from severe sepsis.

Materials and methods

Patients

The Ethical Committee of the University of Vienna approved the study. Seventy patients admitted to a Medical Intensive Care Unit (MICU) of the University of Vienna were assessed for eligibility, all were included in the study. All were randomized and treated, three had to be excluded because of incomplete data, all of the latter survived. Written informed consent was obtained from all participants or their authorized representatives. The criteria for severe sepsis of Bone *et al.* were used.⁹ Patients with a known or suspected infection on the basis of clinical data at the time of screening and three or more signs of systemic inflammation (temperature ≤ 36 or ≥ 38 °C, respiratory rate ≥ 20 /min, heart rate ≥ 90 /min, leukocytes ≤ 4 or ≥ 12 G/L) and sepsis-induced dysfunction of at least two organ systems that lasted no longer than 48 h were included. Treatment with homeopathy or placebo started within 48 h after the patients met the inclusion criteria.

Randomization process

Within 24 h after meeting the criteria for sepsis, all eligible patients were sequentially randomized into two groups, receiving either the homeopathic medicine or placebo, according to a computer-generated code. An independent physician not involved into the study held the code. A person not involved in the decision and/or application process for the study prepared the medication for each patient.

Start of therapy and sublingual administration of the globules

Within 12 h after meeting the criteria for sepsis, homeopathic treatment started. A person not involved in the randomization process poured five globules into the lid of the tube containing the globules, then the globules were poured from the lid directly underneath the patient's tongue. In patients with endotracheal tubes, the globules were administered just aside the endotracheal tube. Globules were given twice daily at an interval of 12 h until sepsis was resolved or until death. Patients were treated for the duration of their stay in the intensive care unit. Treatment stopped on transfer to the general ward. Fifteen minutes before

and after administration of the globules, no oral fluid or food intake or oral hygiene was allowed to avoid any potential interference with the globules. The homeopathic doctors were free to decide which homeopathic medicine should be applied. All medicines were prepared as a 200c (Rote Krebs Apotheke, Vienna, Austria).

Evaluation of patients

Patients were followed for 180 days after the start of treatment unless death occurred earlier. Base-line characteristics including demographic information and information on pre-existing conditions, organ function, markers of disease severity (APACHE II),¹⁰ and infection were assessed within the 24 h before starting treatment. Adverse effects were recorded during the treatment period.

Statistical analysis

The evaluated end point was death within 180 days. Statistical analysis was done at the Department of Medical Computer Sciences, University of Vienna, using the SAS software package (Statistical Analysis System, SAS Institute Inc., Cary, NC). All statistical analyses were done before breaking the randomization code. Statistical analysis of the data was performed using Kruskal–Wallis Test for comparing the two groups.

Results

No adverse effects were observed in either group. Baseline demographic characteristics including age, sex, weight, height, and body mass index (BMI) as well as prior conditions were similar between the two groups (Table 1). Baseline clinical indices including APACHE II score and signs of inflammation, the number of organ failures, the need for mechanical ventilation, vasopressor support, veno-venous pump-driven haemofiltration and positive blood cultures were not significantly different between groups. Only heart rate exceeding 90 beats/min differed significantly, occurring more frequently in the placebo group ($P = 0.033$; Table 2).

On day 30, survival showed a non-statistically significant trend in favour of homeopathy (verum 81.8%, placebo 67.7%, $P = 0.19$; Table 3). On day 180, survival was statistically significantly higher in the verum group 1 (verum 75.8%, placebo 50.0%, $P = 0.043$; Table 3). The most frequently prescribed homeopathic medicines were *Apis mellifica*, *Arsenicum album*, *Baptisia*, *Bryonia*, *Carbo vegetabilis*, *Crotalus horridus*, *Lachesis muta*, *Lycopodium clavatum*, *Phosphorus*, and *Pyrogenium* (Table 4).

Discussion

Our data suggest that adjunctive homeopathic treatment may be beneficial for the survival of critically

Table 1 Baseline demographic characteristics

	Homeopathy n = 33	Placebo n = 34	P
Age	55.1 ± 19.6	58.2 ± 14.0	ns
Age			ns
≤ 60	15 (45.5%)	17 (50.0%)	
61–75	15 (45.5%)	14 (41.2%)	
> 75	3 (9.1%)	3 (8.8%)	
Sex m:f	23:10	21:13	ns
Weight (kg)	79.3 ± 11.9	76.9 ± 11.1	ns
Height (cm)	174.7 ± 8.9	172.0 ± 10.0	ns
BMI	26.2 ± 4.7	26.4 ± 5.5	
Prior conditions			ns
Cancer	12 (36.4%)	13 (38.2%)	
Cardiovascular disease	5 (15.2%)	4 (11.8%)	
Recent trauma	5 (15.2%)	3 (8.8%)	
Infectious disease	3 (9.0%)	3 (8.8%)	
Intoxication	2 (6.1%)	4 (11.8%)	
Renal disease	3 (9.0%)	2 (5.9%)	
Liver disease	1 (3.0%)	2 (5.9%)	
Pneumonia	2 (6.1%)	3 (8.8%)	
Reason for admission			ns
Respiratory insufficiency	12	10	
Sepsis	19	21	
Other	2	3	

Table 2 Baseline clinical indices

	Homeopathy n = 33	Placebo n = 34	P*
APACHE II score	24.7 ± 3.2	24.0 ± 4.4	ns
APACHE II score ≥ 25	18 (54.5%)	16 (47.1%)	ns
Temperature at entry (°C)	37.9 ± 1.34	37.8 ± 1.1	ns
Respiratory rate at entry (min)	21.6 ± 4.6	19.7 ± 5.3	ns
Heart rate at entry (min)	102.7 ± 23.5	112.9 ± 22.2	ns
Leukocytes at entry G/L	13.7 ± 9.4	14.4 ± 10.0	ns
Temperature ≤ 36 or ≥ 38 °C	22 (66.6%)	19 (55.9%)	ns
Respiratory rate ≥ 20 (min)	26 (81.3%)	22 (64.7%)	ns
Heart rate ≥ 90 (min)	22 (66.7%)	30 (90.9%)	0.033
Leukocytes ≤ 4 ≥ 12 G/L	21 (63.6%)	29 (85.3%)	ns
Number of organ failures			ns
2	2 (6.1%)	5 (14.7%)	
3	16 (48.5%)	14 (41.2%)	
4	12 (36.4%)	13 (38.2%)	
5	3 (9.0%)	2 (5.9%)	
Mechanical ventilation	29 (87.9%)	30 (90.9%)	ns
FiO ₂ %	58.6 ± 19.2	65.0 ± 20.9	ns
Vasopressors	26 (78.8%)	30 (88.2%)	ns
Veno-venous hemofiltration	14 (42.4%)	12 (35.3%)	ns
Central venous pressure mmHg	8.7 ± 3.8	9.7 ± 4.7	ns
Blood cultures positive			
Gram negative	7 (21.2%)	4 (11.8%)	ns
Gram positive	4 (12.1%)	6 (17.6%)	ns
Fungi	3 (9.1%)	3 (8.8%)	ns
Mean blood pressure (mmHg)	80.6 ± 16.6	78.2 ± 20.9	ns
Platelet count	158.1 ± 108.0	172.7 ± 136.6	ns
Blood sugar (mmol/l)	8.9 ± 4.3	7.8 ± 2.8	ns
Serum creatinine (μmol/l)	194.5 ± 185.7	185.7 ± 176.8	ns
Blood urea nitrogen (mmol/l)	5.9 ± 4.5	6.0 ± 4.1	ns
Total protein (g/l)	57 ± 8	60 ± 13	ns
Bilirubine (μmol/l)	0.9 ± 0.8	1.1 ± 1.1	ns
Potassium (mmol/l)	4.1 ± 0.7	4.1 ± 0.8	ns
Sodium (mmol/l)	141.9 ± 6.2	142.4 ± 8.7	ns

*Kruskal–Wallis.

ill patients. Short-time survival showed a non-statistically significant trend in favour of homeopathy; however, this may be due to the relatively small sample size. The lack of adverse effects is an important advantage of homeopathic treatment. As a further advantage, there is no interference with traditional treatment. Dosing via the oral route is easy and possible also in intubated patients orally and patients with oral or nasal feeding tubes. Furthermore, homeopathic medicines are low cost. One constraint is the small number of trained homeopathic doctors available in this setting.

Confounding factors include that placebo patients were more seriously affected in terms of heart rate and leukocyte count. However, there was no significant difference in the means of these variables. All patients received antibiotic therapy.

The mortality of severe sepsis, defined as sepsis with at least one organ failure, and septic shock, defined as hypotension not reversible by fluid resuscitation and associated with organ dysfunction or hypoperfusion abnormalities, remains very high despite increased efforts in intensive care medicine.^{11,12}

Guidelines have been developed in an endeavour to improve outcome.¹ Resuscitation of a patient in severe sepsis or sepsis-induced tissue hypoperfusion should begin as soon as the syndrome is recognized and should not be delayed pending ICU admission. During

the first 6 h, the goals should include all of the following: central venous pressure 8–12 mmHg; mean arterial pressure >65 mmHg; urine output >0.5 ml/kg/h; and central venous or mixed venous oxygen saturation >70%. Early therapy directed towards these goals improves survival.¹³

Appropriate cultures should always be obtained before antimicrobial therapy is initiated¹⁴ and tests should be done as soon as possible to determine the source of the infection and the causative organism. Imaging studies such as ultrasound and/or bedside computer tomography should be performed. Sources of infection requiring drainage should be identified

Table 3 Survival

	Homeopathy n = 33	Placebo n = 34	P*
Survival 30 days	27 (81.8%)	23 (67.7%)	0.19
Survival 180 days	25 (75.8%)	17 (50.0%)	0.043

*Kruskal–Wallis.

Table 4 Most often used homeopathic medicines and indications

	Homeopathy number of prescriptions	Placebo number of prescriptions	P
<i>Apis mellifica</i>	4	3	ns
Oedema			
Extreme dyspnoea			
<i>Arsenicum album</i>	6	8	ns
Weakness, exhaustion			
Cardiovascular compromise			
Anxiety, restlessness			
Cachectic appearance			
<i>Baptisia</i>	5	7	ns
ARDS			
Sepsis			
Hot skin			
<i>Belladonna</i>	6	7	ns
High temperature with sweat			
Red discolouration, face			
<i>Bryonia</i>	4	3	ns
Pneumonia, esp. right lung			
Stitching pain in chest			
<i>Carbo vegetabilis</i>	6	7	ns
Respiratory insufficiency			
ARDS			
<i>Crotalus horridus</i>	7	8	ns
Purpura haemorrhagica			
Haemorrhages			
<i>Lachesis muta</i>	15	20	ns
Septic shock			
Haemorrhage			
High temperature			
Embolism			
Discolouration blue, purple			
<i>Lycopodium clavatum</i>	2	4	ns
Fever, afternoon			
Distension, abdominal			
<i>Phosphorus</i>	12	14	ns
Pneumonia, esp. right lower lobe			
Haemorrhage			
Purpura haemorrhagica			
<i>Pyrogenium</i>	5	6	ns
Septic fever			
Offensive odour			

promptly. Intravenous antibiotic therapy should be started within the first hour of recognition of severe sepsis, after appropriate cultures have been obtained.

Establishing vascular access and initiating aggressive fluid resuscitation is the first priority when managing patients with severe sepsis or septic shock. The antimicrobial regimen should always be reassessed after 48–72 h on the basis of microbiological and clinical data with the aim of using a narrow-spectrum antibiotic to prevent the development of resistance, to reduce toxicity, and to reduce costs. Fluid challenge in patients with suspected hypovolemia (suspected inadequate arterial circulation) may be given over 30 min and repeated based on response (increase in blood pressure and urine output) and tolerance (evidence of intravascular volume overload). If appropriate fluid challenge fails to restore adequate blood pressure and organ perfusion, administration with vasopressor agents should be started.

Intravenous corticosteroids are recommended in patients with septic shock who, despite adequate fluid replacement, require vasopressor therapy to maintain

adequate blood pressure.^{15–17} Recombinant activated protein C (rhAPC) is recommended in patients at high risk of death (APACHE II >25, sepsis-induced multiple organ failure, septic shock, or sepsis-induced ARDS) and no absolute contraindication that outweighs the potential benefit of rhAPC. The inflammatory response in sepsis is pro-coagulant in the early stages. rhAPC, an endogenous anti-coagulant with anti-inflammatory properties, has been shown, to improve survival in patients with sepsis-induced organ dysfunction.¹⁸

Mechanical ventilation in sepsis-induced acute lung injury (ALI)/acute respiratory distress syndrome (ARDS) should be adjusted to a “low” tidal volume in conjunction with the goal of maintaining end-inspiratory plateau pressures less than 30 cmH₂O.^{19–22} Daily spontaneous breathing trials reduce the duration of mechanical ventilation.^{23–25} Mechanically ventilated patients receiving continuous sedation may have a significantly longer duration of mechanical ventilation, ICU and hospital length of stay.²⁶ Daily interruption or lightening of sedation may reduce the duration of mechanical ventilation and ICU stay.²⁷ Following initial stabilization, blood glucose should be kept below 8.3 mmol/l using continuous infusion insulin if necessary.²⁸

Conclusion

Our data suggest that homeopathic treatment has a beneficial effect on the long-term survival of patients with severe sepsis, further research is required before making firm recommendations. The lack of trained homeopaths available to advise on treatment on ICUs is an important constraint to further research and implementation.

References

- Dellinger RP, Carlet JM, Masur H, et al. Surviving sepsis campaign guidelines for management of severe sepsis and septic shock. *Intensive Care Med* 2004; **30**: 536–555.
- Brun-Buisson C, Doyon F, Carlet J. Incidence, risk factors, and outcome of severe sepsis and septic shock in adults. A multicenter prospective study in intensive care units. French ICU Group for Severe Sepsis. *JAMA* 1995; **274**: 968–974.
- Reilly DT, Taylor MA, Beattie NGM, et al. Is evidence for homeopathy reproducible? *The Lancet* 1994; **344**: 1601–1606.
- Linde K, Clausius N, Ramirez G, et al. Are the clinical effects of homeopathy placebo effects? A meta-analysis of placebo-controlled trials. *The Lancet* 1997; **350**: 834–843.
- Jacobs J, Jiménez LM, Gloyd SS, et al. Treatment of acute childhood diarrhea with homeopathic medicine: a randomized clinical trial in Nicaragua. *Pediatrics* 1994; **93**: 719–725.
- Samal S, Geckeler KE. Unexpected solute aggregation in water on dilution. *Chem Commun* 2001; 2224–2225.
- Rey L. Thermoluminescence of ultra-high dilutions of lithium chloride and sodium chloride. *Physica A* 2003; **323**: 67–74.

- Frass M. *Durch Ähnliches Heilen—Homöopathie in Österreich*, 2nd edn. Peter König, Orac Verlag, Austria, in press. 61
- Bone RC, Fisher CJ, Clemmer TP, et al. A controlled clinical trial of high-dose methylprednisolone in the treatment of severe sepsis and septic shock. *N Engl J Med* 1987; **317**: 653–658. 63
- Knaus WA, Draper EA, Wagner DP, et al. APACHE II: a severity of disease classification system. *Crit Care Med* 1985; **13**: 818–829. 65
- Dellinger RP. Cardiovascular management of septic shock. *Crit Care Med* 2003; **31**: 946–955. 67
- Friedman G, Silva E, Vincent JL. Has the mortality of septic shock changed with time? *Crit Care Med* 1998; **26**: 2078–2086. 69
- Rivers E, Nguyen B, Havstad S, et al. Early goal-directed therapy in the treatment of severe sepsis and septic shock. *N Engl J Med* 2001; **345**: 1368–1377. 71
- Weinstein MP, Reller LP, Murphy JR, et al. The clinical significance of positive blood cultures: a comprehensive analysis of 500 episodes of bacteremia and fungemia in adults. I. Laboratory and epidemiologic observations. *Rev Infect Dis* 1983; **5**: 35–53. 73
- Annane D, Sebille V, Charpentier C, et al. Effect of treatment with low doses of hydrocortisone and fludrocortisone on mortality in patients with septic shock. *JAMA* 2002; **288**: 862–871. 75
- Briegel J, Forst H, Haller M, et al. Stress doses of hydrocortisone reverse hyperdynamic septic shock: a prospective, randomized, double-blind, single-center study. *Crit Care Med* 1999; **27**: 723–732. 77
- Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. *Crit Care Med* 1998; **26**: 645–650. 79
- Bernard GR, Vincent JL, Laterre PF, et al. Recombinant Human Protein C Worldwide Evaluation in Severe Sepsis (PROWESS) study group. Efficacy and safety of recombinant human activated protein C for severe sepsis. *N Engl J Med* 2001; **344**: 699–709. 81
- Amato MB, Barbas CS, Medeiros DM, et al. Effect of a protective-ventilation strategy on mortality in the acute respiratory distress syndrome. *N Engl J Med* 1998; **338**: 347–354. 83
- Stewart TE, Meade MO, Cook DJ, et al. Evaluation of a ventilation strategy to prevent barotrauma in patients at high risk for acute respiratory distress syndrome Pressure- and Volume-Limited Ventilation Strategy Group. *N Engl J Med* 1998; **338**: 355–361. 85
- Brochard L, Roudat-Thoraval F, et al. Tidal volume reduction for prevention of ventilator-induced lung injury in acute respiratory distress syndrome. The Multicenter Trial Group on Tidal Volume reduction in ARDS. *Am J Respir Crit Care Med* 1998; **158**: 1831–1838. 87
- Brower RG, Shanholtz CB, Fessler HE, et al. Prospective, randomized, controlled clinical trial comparing traditional versus reduced tidal volume ventilation in acute respiratory distress syndrome patients. *Crit Care Med* 1999; **27**: 1492–1498. 89
- Esteban A, Alia I, Tobin MJ, et al. Effect of spontaneous breathing trial duration on outcome of attempts to discontinue mechanical ventilation. Spanish Lung Failure Collaborative Group. *Am J Respir Crit Care Med* 1999; **159**: 512–518. 91
- Ely EW, Baker AM, Dunagan DP, et al. Effect on the duration of mechanical ventilation of identifying patients capable of breathing spontaneously. *N Engl J Med* 1996; **335**: 1864–1869. 93
- Esteban A, Alia I, Gordo F, et al. Extubation outcome after spontaneous breathing trials with T-tube or pressure support ventilation. The Spanish Lung Failure Collaborative Group. *Am J Respir Crit Care Med* 1997; **156**: 459–465. 95

6

1 26 Kollef MH, Levy NT, Ahrens TS, et al. The use of continuous
3 IV sedation is associated with prolongation of mechanical
4 ventilation. *Chest* 1998; **114**: 541–548.

5 27 Kress JP, Pohlman AS, O'Connor MF, et al. Daily interrup-
6 tion of sedative infusions in critically ill patients undergoing
7 mechanical ventilation. *N Engl J Med* 2000; **342**: 1471–1477.

28 Berghe G van den, Wouters P, Weekers F, et al. Intensive
9 insulin therapy in the critically ill patients. *N Engl J Med* 2001;
10 **345**: 1359–1367.

11

UNCORRECTED PROOF